Table 4.
Logistic regression analysis of the factors associated with sustained virological response
| Variable | RR (95% CI) | P-value |
|---|---|---|
| Univariate analysis | ||
| Pretreatment variables | ||
| Gender (male vs. female) | 1.190 (0.581–2.438) | 0.635 |
| Age (≥55 vs. <55 years) | 1.273 (0.618–2.625) | 0.512 |
| Weight (<60 vs. ≥60 kg) | 1.064 (0.520–2.175) | 0.865 |
| Treatment (re-treatment vs. naive) | 1.468 (0.428–5.051) | 0.541 |
| Genotype (1 vs. 2) | 2.247 (0.690–7.299) | 0.179 |
| Fibrosis staging (F2-4 vs. F0-1)† | 1.964 (0.812–4.749) | 0.134 |
| Grading (A2-3 vs. A0-1)† | 4.343 (1.727–10.922) | 0.002 |
| HCV RNA (kIU/mL) <100 | 1 | |
| 100–1000 | 0.367 (0.138–0.975) | 0.044 |
| ≥1000 | 0.115 (0.044–0.298) | <0.001 |
| ALT (≥41 vs. <41 IU/l) | 4.570 (2.104–9.927) | <0.001 |
| γ-GTP (IU/l) (≥28 vs. <28 IU/l) | 6.182 (2.657–14.384) | <0.001 |
| Neutrophil count (<3155 vs. ≥3155/μl) | 3.135 (1.479–6.623) | 0.003 |
| Hemoglobin (≥14 vs. <14 g/dl) | 1.125 (0.555–2.283) | 0.744 |
| Platelet count (<150 vs. ≥150 × 103/μl) | 1.091 (0.507–2.347) | 0.824 |
| Treatment-associated variables | ||
| RVR (yes vs. no) | 6.818 (2.482–18.733) | <0.001 |
| Adherence (≥80% vs. <80%) | 1.940 (0.949–3.966) | 0.070 |
| Stepwise Multivariate Analysis‡ | ||
| HCV RNA (kIU/ml) | ||
| <100 | 1 | |
| 100–1000 | 0.165 (0.046–0.589) | 0.006 |
| ≥1000 | 0.102 (0.029–0.352) | <0.001 |
| RVR (yes vs. no) | 6.223 (1.821–21.305) | 0.003 |
| ALT (≥41 vs. <41 IU/l) | 4.775 (1.373–16.601) | 0.014 |
| γ-GTP (IU/l) (≥28 vs. <28 IU/l) | 3.466 (1.092–11.000) | 0.035 |
ALT alanine aminotransferase, γ-GTP gamma glutamyl transpeptidase, RVR rapid virological response
†A biopsy was not available from 40 patients
‡Grading was not included